B. Deschler and M. Lubbert, Acute myeloid leukemia: epidemiology and etiology, Cancer, vol.107, pp.2099-107, 2006.

K. R. Rai, J. F. Holland, O. J. Glidewell, V. Weinberg, K. Brunner et al., Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B, Blood, vol.58, pp.1203-1215, 1981.

J. F. Bishop, Adult acute myeloid leukaemia: update on treatment, Med J Aust, vol.170, pp.39-43, 1999.

E. Estey and H. Dohner, Acute myeloid leukaemia, Lancet, vol.368, pp.1894-907, 2006.

M. S. Tallman, D. G. Gilliland, and J. M. Rowe, Drug therapy for acute myeloid leukemia, Blood, vol.106, pp.1154-63, 2005.

H. F. Fernandez and J. M. Rowe, Induction therapy in acute myeloid leukemia: intensifying and targeting the approach, Curr Opin Hematol, vol.17, pp.79-84, 2010.

H. F. Fernandez, Z. Sun, X. Yao, M. R. Litzow, S. M. Luger et al., Anthracycline dose intensification in acute myeloid leukemia, N Engl J Med, vol.361, pp.1249-59, 2009.

M. A. Sekeres, Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives, Haematologica, vol.93, pp.1769-72, 2008.

D. J. Fitzgerald, A. S. Wayne, R. J. Kreitman, and I. Pastan, Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates, Cancer Res, vol.71, pp.6300-6309, 2011.

P. R. Hamann, L. M. Hinman, I. Hollander, C. F. Beyer, D. Lindh et al., Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibodycalicheamicin conjugate for treatment of acute myeloid leukemia, Bioconjug Chem, vol.13, pp.47-58, 2002.

A. D. Ricart, Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin, Clin Cancer Res, vol.17, pp.6417-6444, 2011.

S. Castaigne, C. Pautas, C. Terre, E. Raffoux, D. Bordessoule et al., Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study, Lancet, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01056520

H. Farhat, O. Reman, E. Raffoux, C. Berthon, C. Pautas et al., Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association, Am J Hematol, vol.87, pp.62-67, 2012.

A. L. Taksin, O. Legrand, E. Raffoux, T. De-revel, X. Thomas et al., High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group, Leukemia, vol.21, pp.66-71, 2007.

M. Thomas, J. Clarhaut, P. O. Strale, I. Tranoy-opalinski, J. Roche et al., A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells, ChemMedChem, vol.6, pp.1006-1016, 2011.

I. Tranoy-opalinski, A. Fernandes, M. Thomas, J. P. Gesson, and S. Papot, Design of selfimmolative linkers for tumour-activated prodrug therapy, Anticancer Agents Med Chem, vol.8, pp.618-655, 2008.

N. Parker, M. J. Turk, E. Westrick, J. D. Lewis, P. S. Low et al., Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay, Anal Biochem, vol.338, pp.284-93, 2005.

J. F. Ross, H. Wang, F. G. Behm, P. Mathew, M. Wu et al., Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia, Cancer, vol.85, pp.348-57, 1999.

T. Legigan, J. Clarhaut, B. Renoux, I. Tranoy-opalinski, A. Monvoisin et al., Synthesis and antitumor efficacy of a beta-glucuronidase-responsive albumin-binding prodrug of doxorubicin, J Med Chem, vol.55, pp.4516-4536, 2012.

J. Clarhaut, R. M. Gemmill, V. A. Potiron, A. , S. Imbert et al., ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells, Neoplasia, vol.11, pp.157-66, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00416521

A. Niemisto, V. Dunmire, O. Yli-harja, W. Zhang, and I. Shmulevich, Robust quantification of in vitro angiogenesis through image analysis, IEEE Trans Med Imag, vol.24, pp.549-53, 2005.

V. A. Potiron, G. Sharma, P. Nasarre, J. A. Clarhaut, H. G. Augustin et al., Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells, Cancer Res, vol.67, pp.8708-8723, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00416414

J. Ducroq, H. Moha-ou-maati, S. Guilbot, S. Dilly, E. Laemmel et al., Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks), Br J Pharmacol, vol.159, pp.93-101, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00561579

X. Q. Pan, X. Zheng, G. Shi, H. Wang, M. Ratnam et al., Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid, Blood, vol.100, pp.594-602, 2002.

J. Liu, W. Mao, B. Ding, and C. S. Liang, ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes, Am J Physiol Heart Circ Physiol, vol.295, pp.1956-65, 2008.

W. Xia and P. S. Low, Folate-targeted therapies for cancer, J Med Chem, vol.53, pp.6811-6835, 2010.

M. S. Tallman, New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents, Hematology Am Soc Hematol Educ Program, pp.143-50, 2005.

C. P. Leamon, Folate-targeted drug strategies for the treatment of cancer, Curr Opin Investig Drugs, vol.9, pp.1277-86, 2008.

C. P. Leamon and J. A. Reddy, Folate-targeted chemotherapy, Adv Drug Deliv Rev, vol.56, pp.1127-1168, 2004.

J. A. Reddy, V. M. Allagadda, and C. P. Leamon, Targeting therapeutic and imaging agents to folate receptor positive tumors, Curr Pharm Biotechnol, vol.6, pp.131-50, 2005.

H. Elnakat and M. Ratnam, Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Adv Drug Deliv Rev, vol.56, pp.1067-84, 2004.

R. M. Sandoval, M. D. Kennedy, P. S. Low, and B. A. Molitoris, Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy, Am J Physiol Cell Physiol, vol.287, pp.517-543, 2004.

A. R. Hilgenbrink and P. S. Low, Folate receptor-mediated drug targeting: from therapeutics to diagnostics, J Pharm Sci, vol.94, pp.2135-2181, 2005.

P. S. Low, W. A. Henne, and D. D. Doorneweerd, Discovery and development of folic-acidbased receptor targeting for imaging and therapy of cancer and inflammatory diseases, Acc Chem Res, vol.41, pp.120-129, 2008.

P. S. Low and S. A. Kularatne, Folate-targeted therapeutic and imaging agents for cancer, Curr Opin Chem Biol, vol.13, pp.256-62, 2009.

J. A. Reddy, E. Westrick, H. K. Santhapuram, S. J. Howard, M. L. Miller et al., Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate, Cancer Res, vol.67, pp.6376-82, 2007.

L. Ducry and B. Stump, Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies, Bioconjug Chem, vol.21, pp.5-13, 2010.

M. N. Saleh, S. Sugarman, J. Murray, J. B. Ostroff, D. Healey et al., Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors, J Clin Oncol, vol.18, pp.2282-92, 2000.

H. Xie, C. Audette, M. Hoffee, J. M. Lambert, and W. A. Blattler, Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice, J Pharmacol Exp Ther, vol.308, pp.1073-82, 2004.

T. Legigan, J. Clarhaut, I. Tranoy-opalinski, A. Monvoisin, B. Renoux et al., The first génération of ?-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy, Angewandte Chemie, vol.51, pp.11606-11616, 2012.